Insulin-like growth factor mimetics for use in therapy
US-2016271265-A1 · Sep 22, 2016 · US
Stabilized insulin-like growth factor polypeptides
US10167329B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10167329-B2 |
| Application number | US-201314651686-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 16, 2013 |
| Priority date | Dec 18, 2012 |
| Publication date | Jan 1, 2019 |
| Grant date | Jan 1, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention is in the field of IGF-1 modifications. In particular, it relates to modified IGF-polypeptides and modified IGF-1 precursor polypeptides wherein the cleavage of E-peptide is prevented. The invention also relates to the use of such polypeptides for treating muscle diseases and disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. A polypeptide comprising a human IGF-1 protein variant of SEQ ID NO: 1 wherein the amino acid glycine at position 42 is mutated to serine. 2. The polypeptide of claim 1 , wherein the human IGF-1 protein variant is fused to an immunoglobulin Fc region of a human IgG, optionally by a peptide hinge region. 3. The polypeptide of claim 1 , wherein the polypeptide is glycosylated. 4. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier. 5. A polypeptide comprising a human IGF-1 protein variant of SEQ ID NO: 1 wherein the human IGF-1 protein variant has the following modifications: a. amino acid E3 is deleted, b. amino acid G42 is mutated to serine, and c. amino acid R37 is mutated to alanine. 6. A polypeptide comprising a human IGF-1 protein variant of SEQ ID NO: 1 wherein the human IGF-1 protein variant comprises the following modifications: a. amino acids G1, P2, E3 are deleted; b. amino acid G42 is mutated to serine; c. amino acid R36 is mutated to glutamine; and d. amino acid R37 is mutated to alanine. 7. A pharmaceutical composition comprising the polypeptide of claim 6 and a pharmaceutically acceptable carrier. 8. The polypeptide of claim 6 , wherein the human IGF-1 protein variant is fused to an immunoglobulin Fc region of a human IgG, optionally by a peptide hinge region. 9. A polypeptide comprising a human IGF-1 protein variant of SEQ ID NO: 1 wherein the human IGF-1 protein variant comprises the following modifications: a. amino acids G1, P2, E3 are deleted, b. amino acid G42 is mutated to serine, and c. amino acid R37 is mutated to alanine. 10. A pharmaceutical composition comprising the polypeptide of claim 9 and a pharmaceutically acceptable carrier. 11. The polypeptide of claim 9 , wherein the human IGF-1 protein variant is fused to an immunoglobulin Fc region of a human IgG, optionally by a peptide hinge region. 12. A polypeptide comprising a human IGF-1 protein variant of SEQ ID NO: 1 wherein the amino acid G42 is substituted by the amino acid serine and wherein the amino acid(s): (a) G1, P2, E3 are deleted and amino acid R36 is substituted or deleted; or (b) G1, P2, E3 are deleted and amino acid R36 is substituted by glutamine (Q); or (c) G1, P2, E3 are deleted and amino acid R37 is substituted or deleted; or (d) G1, P2, E3 are deleted and amino acid R37 is substituted by glutamic acid (E); or (e) G1, P2, E3 are deleted and amino acid R37 is substituted by alanine; or (f) G1, P2, E3 are deleted and amino acid R37 is substituted by proline (P); or (g) G1, P2, E3 are deleted and amino acids R36 and R37 are substituted or deleted; or (h) G1, P2, E3 are deleted and amino acid R36 and R37 are both substituted by glutamine (Q); or (i) G1, P2, E3 are deleted, amino acid R36 is substituted by glutamine (Q) and R37 is substituted by alanine. 13. A pharmaceutical composition comprising the polypeptide of claim 12 and a pharmaceutically acceptable carrier. 14. The polypeptide of claim 12 , wherein the human IGF-1 protein variant is fused to an immunoglobulin Fc region of a human IgG, optionally by a peptide hinge region.
Assignees
Inventors
Classifications
Drugs for disorders of the respiratory system · CPC title
Drugs for skeletal disorders · CPC title
for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title
Drugs for disorders of the muscular or neuromuscular system · CPC title
of the kidneys · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10167329B2 cover?
- This invention is in the field of IGF-1 modifications. In particular, it relates to modified IGF-polypeptides and modified IGF-1 precursor polypeptides wherein the cleavage of E-peptide is prevented. The invention also relates to the use of such polypeptides for treating muscle diseases and disorders.
- Who is the assignee on this patent?
- Fornaro Mara, Huber Thomas, Zurini Mauro, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/65. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).